ArticleJapanese journal of ophthalmology2026
Real-world outcomes of anti-VEGF and corticosteroid therapies for diabetic macular edema: up to 10 years of follow-up in Korean patients.
Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intravitreal Brolucizumab for Diabetic Macular Edema: Outcomes in Treatment-Naive and Anti-VEGF-Switched Eyes over 48 Weeks.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeTo examine the long-term real-world outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) and corticosteroid injections in patients with diabetic macular edema (DME). STUDY
designSingle-center, retrospective study.
methodsWe reviewed the medical records of patients diagnosed with DME between January 2010 and December 2023. The number of anti-VEGF and corticosteroid injections, along with best-corrected visual acuity (BCVA) and central macular thickness (CMT), were collected and analyzed throughout the follow-up period.
resultsA total of 574 patients (774 eyes) were included, with a mean follow-up of 5.1 ± 4.7 years. The mean anti-VEGF injections was 3.6 ± 2.3 times in the first year, significantly decreasing to 1.6 ± 2.0 in the second year (p < 0.001) and 0.29 ± 1.1 by the tenth year. In contrast, corticosteroid injections remained low and stable over ten years (0.16 ± 0.49 in the first year; 0.16 ± 0.68 in the tenth year). Baseline BCVA was 0.43 ± 0.36 logMAR, significantly improving to 0.27 ± 0.29 at year 1 (p < 0.001) and remained stable at 0.32 ± 0.31 by year 10. Mean CMT decreased from 423.1 ± 121.3 μm at baseline to 333.4 ± 93.8 μm in year 1 (p < 0.001), and continued to decline over 10 years, reaching 279.3 ± 71.2 μm.
conclusionThis 10-year real-world study confirms the effectiveness of anti-VEGF and corticosteroid injections in achieving functional and anatomical improvements in DME, although the outcomes were less favorable than those reported in clinical trials, primarily due to undertreatment and patient heterogeneity.
Indexed as
Identifiers
41186662What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.